Cargando…
The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis
BACKGROUND: Liraglutide has been shown to improve glucose tolerance and lose weight in individuals with type 2 diabetes. To date, no meta-analysis of liraglutide's safety and efficacy in individuals without diabetes has been conducted. OBJECTIVES: The aim of this study is to carry out a meta-an...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Makerere Medical School
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040262/ https://www.ncbi.nlm.nih.gov/pubmed/32127832 http://dx.doi.org/10.4314/ahs.v19i3.35 |
_version_ | 1783500948278083584 |
---|---|
author | Zhang, Pei Liu, Yu Ren, Yuan Bai, Jie Zhang, Guangzhen Cui, Yuanshan |
author_facet | Zhang, Pei Liu, Yu Ren, Yuan Bai, Jie Zhang, Guangzhen Cui, Yuanshan |
author_sort | Zhang, Pei |
collection | PubMed |
description | BACKGROUND: Liraglutide has been shown to improve glucose tolerance and lose weight in individuals with type 2 diabetes. To date, no meta-analysis of liraglutide's safety and efficacy in individuals without diabetes has been conducted. OBJECTIVES: The aim of this study is to carry out a meta-analysis to assess the efficacy and safety of liraglutide in the obese, non-diabetic individuals. METHODS: A literature review was performed to identify all published randomised control trials (RCT) of liraglutide for the treatment of obesity in non-diabetic individuals. The search included the following databases: EMBASE, MEDLINE and the Cochrane Controlled Trials Register. RESULTS: We included five publications involving a total of 4,754 patients that compared liraglutide with placebo and found that liraglutide to be an effective and safe treatment for weight loss in individuals without diabetes. Primary efficacy end points: mean weight loss (MD = -5.52, 95% CI = -5.93 to -5.11, p<0.00001); lost more than 5% of body weight (OR = 5.46, 95% CI=3.57 to 8.34, p<0.00001) and key secondary efficacy end points: SBP decreased (the MD = -2.56, 95% CI = -3.28 to -1.84, p<0.00001). Safety assessments included the proportion of individuals who were withdrawn due to AE (OR = 2.85, 95% CI= 0.84 to 9.62, p=0.009), and nausea indicated that liraglutide was well tolerated. CONCLUSION: This systematic review and meta-analysis indicates that liraglutide to be an effective and safe treatment for weight loss in the obese, non-diabetic individuals. |
format | Online Article Text |
id | pubmed-7040262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Makerere Medical School |
record_format | MEDLINE/PubMed |
spelling | pubmed-70402622020-03-03 The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis Zhang, Pei Liu, Yu Ren, Yuan Bai, Jie Zhang, Guangzhen Cui, Yuanshan Afr Health Sci Articles BACKGROUND: Liraglutide has been shown to improve glucose tolerance and lose weight in individuals with type 2 diabetes. To date, no meta-analysis of liraglutide's safety and efficacy in individuals without diabetes has been conducted. OBJECTIVES: The aim of this study is to carry out a meta-analysis to assess the efficacy and safety of liraglutide in the obese, non-diabetic individuals. METHODS: A literature review was performed to identify all published randomised control trials (RCT) of liraglutide for the treatment of obesity in non-diabetic individuals. The search included the following databases: EMBASE, MEDLINE and the Cochrane Controlled Trials Register. RESULTS: We included five publications involving a total of 4,754 patients that compared liraglutide with placebo and found that liraglutide to be an effective and safe treatment for weight loss in individuals without diabetes. Primary efficacy end points: mean weight loss (MD = -5.52, 95% CI = -5.93 to -5.11, p<0.00001); lost more than 5% of body weight (OR = 5.46, 95% CI=3.57 to 8.34, p<0.00001) and key secondary efficacy end points: SBP decreased (the MD = -2.56, 95% CI = -3.28 to -1.84, p<0.00001). Safety assessments included the proportion of individuals who were withdrawn due to AE (OR = 2.85, 95% CI= 0.84 to 9.62, p=0.009), and nausea indicated that liraglutide was well tolerated. CONCLUSION: This systematic review and meta-analysis indicates that liraglutide to be an effective and safe treatment for weight loss in the obese, non-diabetic individuals. Makerere Medical School 2019-09 /pmc/articles/PMC7040262/ /pubmed/32127832 http://dx.doi.org/10.4314/ahs.v19i3.35 Text en © 2019 Zhang et al. Licensee African Health Sciences. This is an Open Access article distributed under the terms of the Creative commons Attribution License (https://creativecommons.org/licenses/BY/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Zhang, Pei Liu, Yu Ren, Yuan Bai, Jie Zhang, Guangzhen Cui, Yuanshan The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis |
title | The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis |
title_full | The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis |
title_fullStr | The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis |
title_full_unstemmed | The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis |
title_short | The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis |
title_sort | efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040262/ https://www.ncbi.nlm.nih.gov/pubmed/32127832 http://dx.doi.org/10.4314/ahs.v19i3.35 |
work_keys_str_mv | AT zhangpei theefficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis AT liuyu theefficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis AT renyuan theefficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis AT baijie theefficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis AT zhangguangzhen theefficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis AT cuiyuanshan theefficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis AT zhangpei efficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis AT liuyu efficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis AT renyuan efficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis AT baijie efficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis AT zhangguangzhen efficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis AT cuiyuanshan efficacyandsafetyofliraglutideintheobesenondiabeticindividualsasystematicreviewandmetaanalysis |